Publication
Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Daniel Nguyen, Hagop M Kantarjian, Aram Bidikian, Christopher M Manuel, Wei Qiao, Jing Ning, Courtney D DiNardo, Tapan M Kadia, Naval Daver, Gautam Borthakur, Elias Jabbour, Musa Yilmaz, Abhishek Maiti, Koji Sasaki, Guillermo Montalban-Bravo, Kelly Chien, Danielle Hammond, Sherry Pierce, Michael Andreeff, Farhad Ravandi, Nicholas J Short, Guillermo Garcia-Manero, Ghayas C Issa
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
PURPOSE: Outcomes in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remain discouraging despite the rapid expansion of treatment paradigms over the past decade. Clinicians must often decide between conventional salvage treatment regimens or enrollment in clinical…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerLeukemiadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available